---
title: Ultrasound-guided Ilioinguinal-iliohypogastric Block for Inguinal Hernia Repair
nct_id: NCT01326039
overall_status: UNKNOWN
phase: PHASE4
sponsor: Bispebjerg Hospital
study_type: INTERVENTIONAL
primary_condition: Inguinal Hernia
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01326039.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01326039"
ct_last_update_post_date: 2011-03-30
last_seen_at: "2026-05-12T06:27:33.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Ultrasound-guided Ilioinguinal-iliohypogastric Block for Inguinal Hernia Repair

**Official Title:** Does Ultrasound-guided Ilioinguinal-iliohypogastric Block Improve Postoperative Pain Outcome After Unilateral Inguinal Hernia Repair?

**NCT ID:** [NCT01326039](https://clinicaltrials.gov/study/NCT01326039)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Bispebjerg Hospital
- **Conditions:** Inguinal Hernia
- **Start Date:** 2010-05
- **Completion Date:** 2011-07
- **CT.gov Last Update:** 2011-03-30

## Brief Summary

Aim: To investigate whether ultrasound-guided perineural administration of 20 ml bupivacaine 5 mg/ml vs 20 ml isotonic saline at the ilioinguinal-iliohypogastric nerves have a clinically analgesic effect after unilateral open inguinal hernia repair.

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* age above 18 years
* unilateral primary inguinal repair
* open surgery a.m. Lichtenstein
* informed consent

Exclusion Criteria:

* age below 18 years
* secondary surgery
* laparoscopic surgery
* lack of communicative skills
```

## Arms

- **bupivacaine** (ACTIVE_COMPARATOR) — perineural bupivacaine 5 mg/ml 20 ml
- **saline** (PLACEBO_COMPARATOR) — perineural isotonic saline 20 ml

## Interventions

- **bupivacaine** (DRUG) — perineural bupivacaine 5 mg/ml 20 ml
- **saline** (DRUG) — perineural isotonic saline 20 ml

## Primary Outcomes

- **pain at mobilization using 100 mm VAS** _(time frame: within the first 24 hours postoperatively)_

## Secondary Outcomes

- **pain at rest using 100 mm VAS** _(time frame: within 24 hours postoperatively)_
- **perceived illness** _(time frame: within 24 hours postoperatively)_
- **ability of daily living** _(time frame: within 24 hours)_
- **amount of analgesics** _(time frame: within 24 hours postoperatively)_

## Locations (1)

- Copenhagen University Hospital Bispebjerg, Copenhagen, NV, Denmark — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.copenhagen university hospital bispebjerg|copenhagen|nv|denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01326039.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01326039*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*